Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of predictors of disease progression in aHUS patients on eculizumab (Germany registry subset)
2015-003135-35Phase 4Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Rate of TMA manifestations. Started Feb 2016; status: terminated.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2015-003135-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003135-35.